Endocrine Abstracts

Background: Diabetes mellitus (DM) is increasing because of urbanization, aging, growth in population, physical inactivity, and excess body weight. The management of diabetes is an important issue for Uzbekistan both from medical and socio-economic points of view due to the increase in the number of patients with type 2 diabetes (T2DM), resulting in disability and premature mortality. This study aims to summarize the recent status of diabetes care in Uzbekistan and to analyze the current treatment of diabetes in the Fergana region.

Materials and methods: To describe the current healthcare for DM in Uzbekistan, recommendations for diabetes treatment in Uzbekistan, reports from international organizations, and research papers were used. Besides, the treatment of T2DM in the Fergana region, 2022, was analyzed.

Results: In 2022, a total of 230,610 patients with DM, composed of 18,349 type 1 diabetes and 212,261 T2DM were registered in the National Registry of Diabetes. Among patients with T2DM in the Fergana region, monotherapy was the most common (71.0%), followed by dual combination therapy of two anti-diabetic drugs (28.1%). Only 0.9% of the patients with T2DM received no medications. Among monotherapies of DM, insulin (25.3%) was the most common, followed by biguanides (23.4%), sulfonylureas (20.8%), and thiazolidinediones (1.5%). Among dual combination therapies, biguanides+sulfonylureas (24.5%) was the most common.

Conclusion: Insulin monotherapy, biguanides, sulfonylureas, and biguanides+sulfonylureas were the most common medications for T2DM in the Fergana region. Insulin monotherapy was the most common in the older age groups and patients with longer durations of T2DM.

Keywords: type 2 diabetes, prevalence, treatment, policy, Uzbekistan